Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von A Kopp-Derouet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hôpitaux Saint-Louis/Lariboisière, APHP, Hôpital Lariboisière, 2, rue Ambroise Paré, 75475, Paris Cedex 10, France. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, COVID-19, Length of Stay, Hospitalization. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
During the first pandemic of COVID-19, early empirical antibiotic use rates for pneumonia varied widely. The benefit remains hypothetical.
Methods
We assessed the benefit of empirical antibiotic use at admission in patients hospitalized with COVID-19 pneumonia. We enrolled all adults admitted from 1 March to 30 April 2020 with symptoms for ≤14 days, a positive nasopharyngeal PCR or a highly suggestive CT scan. The primary outcome was mortality at Day 28. The secondary outcomes were transfer to the ICU, mechanical ventilation and length of hospital stay. To handle confounding-by-indication bias, we used a propensity score analysis, expressing the outcomes in the original and overlap weighted populations.
Results
Among 616 analysed patients, 402 (65%) received antibiotics. At Day 28, 102 patients (17%) had died, 90 (15%) had been transferred to the ICU and 24 (4%) had required mechanical ventilation. Mortality in patients who received antibiotics was higher before but not after weighting (OR 2.7, 95% CI 1.5–5.0, P < 0.001 and OR 1.4, 95% CI 0.8–2.5, P = 0.28, respectively. Antibiotic use had no benefit on: transfer to ICU before and after weighting (OR 1.3, 95% CI 0.8–2.3, P = 0.30 and OR 1.1, 95% CI 0.6–1.9, P = 0.78, respectively); mechanical ventilation before and after weighting (OR 0.5, 95% CI 0.2–1.1, P = 0.079 and OR 0.75, 95% CI 0.3–2.0, P = 0.55, respectively); and length of hospital stay before and after weighting (mean difference −0.02 ± 0.5 days, P = 0.97 and mean difference 0.54 ± 0.75 days, P = 0.48, respectively).
Conclusions
We did not find any benefit of antibiotic use in patients hospitalized with COVID-19 pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Department, Hôpitaux Saint-Louis/Lariboisière, APHP, Hôpital Lariboisière, 2, rue Ambroise Paré, 75475, Paris Cedex 10, France.
- Université de Paris Cité, Paris, France.
- Infectious Diseases and Internal Medicine Department, GH SIF, Melun, France.
- DYNAMIC Unit, UPEC, Créteil, France.
- Department of Biostatistics and Medical Informatics, Hôpitaux Saint-Louis/Lariboisière, APHP, Paris, France.
- Department of Respiratory Diseases, Hôpitaux Saint-Louis/Lariboisière, APHP, Paris, France.
Zitieren
APA
Kopp-Derouet, A., Diamantis, S., Chevret, S., Tazi, A., Burlacu, R., Kevorkian, J. P., Julla, J. B., Molina, J. M., & Sellier, P. (2024). Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae350
Vancouver
Kopp-Derouet A, Diamantis S, Chevret S, Tazi A, Burlacu R, Kevorkian JP, et al. Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae350
BibTeX
@article{KoppDerouet2024,
author = {Kopp-Derouet, A and Diamantis, S and Chevret, S and Tazi, A and Burlacu, R and Kevorkian, J P and Julla, J B and Molina, J M and Sellier, P},
title = {Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae350}
}
EUVIMED